Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
A retrospective subgroup analysis of a Phase II study (Study 19) shows the effect that an investigational drug, olaparib, has on progression-free survival (PFS) compared with placebo in platinum-sensitive relapsed serous ovarian cancer patients with BRCA mutations.
Help employers find you! Check out all the jobs and post your resume.
